vs

Side-by-side financial comparison of ONESPAWORLD HOLDINGS Ltd (OSW) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $207.3M, roughly 1.2× Ultragenyx Pharmaceutical Inc.). ONESPAWORLD HOLDINGS Ltd runs the higher net margin — 5.0% vs -62.0%, a 67.0% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 11.5%). ONESPAWORLD HOLDINGS Ltd produced more free cash flow last quarter ($14.9M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 7.1%).

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

OSW vs RARE — Head-to-Head

Bigger by revenue
OSW
OSW
1.2× larger
OSW
$242.1M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+14.4% gap
RARE
25.9%
11.5%
OSW
Higher net margin
OSW
OSW
67.0% more per $
OSW
5.0%
-62.0%
RARE
More free cash flow
OSW
OSW
$115.7M more FCF
OSW
$14.9M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
7.1%
OSW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OSW
OSW
RARE
RARE
Revenue
$242.1M
$207.3M
Net Profit
$12.1M
$-128.6M
Gross Margin
Operating Margin
6.8%
-54.7%
Net Margin
5.0%
-62.0%
Revenue YoY
11.5%
25.9%
Net Profit YoY
-16.2%
3.5%
EPS (diluted)
$0.12
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OSW
OSW
RARE
RARE
Q4 25
$242.1M
$207.3M
Q3 25
$258.5M
$159.9M
Q2 25
$240.7M
$166.5M
Q1 25
$219.6M
$139.3M
Q4 24
$217.2M
$164.6M
Q3 24
$241.7M
$139.5M
Q2 24
$224.9M
$147.0M
Q1 24
$211.2M
$108.8M
Net Profit
OSW
OSW
RARE
RARE
Q4 25
$12.1M
$-128.6M
Q3 25
$24.3M
$-180.4M
Q2 25
$19.9M
$-115.0M
Q1 25
$15.3M
$-151.1M
Q4 24
$14.4M
$-133.2M
Q3 24
$21.6M
$-133.5M
Q2 24
$15.8M
$-131.6M
Q1 24
$21.2M
$-170.7M
Operating Margin
OSW
OSW
RARE
RARE
Q4 25
6.8%
-54.7%
Q3 25
10.2%
-106.9%
Q2 25
9.2%
-64.8%
Q1 25
7.7%
-102.6%
Q4 24
7.9%
-74.3%
Q3 24
10.3%
-94.6%
Q2 24
8.4%
-79.1%
Q1 24
8.0%
-151.9%
Net Margin
OSW
OSW
RARE
RARE
Q4 25
5.0%
-62.0%
Q3 25
9.4%
-112.8%
Q2 25
8.3%
-69.0%
Q1 25
7.0%
-108.5%
Q4 24
6.6%
-80.9%
Q3 24
8.9%
-95.7%
Q2 24
7.0%
-89.5%
Q1 24
10.0%
-156.8%
EPS (diluted)
OSW
OSW
RARE
RARE
Q4 25
$0.12
$-1.28
Q3 25
$0.23
$-1.81
Q2 25
$0.19
$-1.17
Q1 25
$0.15
$-1.57
Q4 24
$0.13
$-1.34
Q3 24
$0.20
$-1.40
Q2 24
$0.15
$-1.52
Q1 24
$0.21
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OSW
OSW
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$16.3M
$421.0M
Total DebtLower is stronger
$84.0M
Stockholders' EquityBook value
$542.6M
$-80.0M
Total Assets
$707.1M
$1.5B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OSW
OSW
RARE
RARE
Q4 25
$16.3M
$421.0M
Q3 25
$29.6M
$202.5M
Q2 25
$35.0M
$176.3M
Q1 25
$22.6M
$127.1M
Q4 24
$57.4M
$174.0M
Q3 24
$48.8M
$150.6M
Q2 24
$62.5M
$480.7M
Q1 24
$65.4M
$112.3M
Total Debt
OSW
OSW
RARE
RARE
Q4 25
$84.0M
Q3 25
$85.2M
Q2 25
$96.2M
Q1 25
$97.4M
Q4 24
$98.6M
Q3 24
$98.7M
Q2 24
$123.8M
Q1 24
$138.6M
Stockholders' Equity
OSW
OSW
RARE
RARE
Q4 25
$542.6M
$-80.0M
Q3 25
$552.8M
$9.2M
Q2 25
$548.3M
$151.3M
Q1 25
$530.6M
$144.2M
Q4 24
$554.5M
$255.0M
Q3 24
$540.1M
$346.8M
Q2 24
$532.7M
$432.4M
Q1 24
$515.5M
$140.3M
Total Assets
OSW
OSW
RARE
RARE
Q4 25
$707.1M
$1.5B
Q3 25
$732.6M
$1.2B
Q2 25
$731.8M
$1.3B
Q1 25
$708.7M
$1.3B
Q4 24
$746.4M
$1.5B
Q3 24
$734.0M
$1.5B
Q2 24
$756.8M
$1.6B
Q1 24
$763.6M
$1.3B
Debt / Equity
OSW
OSW
RARE
RARE
Q4 25
0.15×
Q3 25
0.15×
Q2 25
0.18×
Q1 25
0.18×
Q4 24
0.18×
Q3 24
0.18×
Q2 24
0.23×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OSW
OSW
RARE
RARE
Operating Cash FlowLast quarter
$20.0M
$-99.8M
Free Cash FlowOCF − Capex
$14.9M
$-100.8M
FCF MarginFCF / Revenue
6.2%
-48.6%
Capex IntensityCapex / Revenue
2.1%
0.5%
Cash ConversionOCF / Net Profit
1.65×
TTM Free Cash FlowTrailing 4 quarters
$68.4M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OSW
OSW
RARE
RARE
Q4 25
$20.0M
$-99.8M
Q3 25
$33.2M
$-91.4M
Q2 25
$20.3M
$-108.3M
Q1 25
$10.1M
$-166.5M
Q4 24
$16.6M
$-79.3M
Q3 24
$28.6M
$-67.0M
Q2 24
$18.7M
$-77.0M
Q1 24
$15.0M
$-190.7M
Free Cash Flow
OSW
OSW
RARE
RARE
Q4 25
$14.9M
$-100.8M
Q3 25
$27.6M
$-92.7M
Q2 25
$17.6M
$-110.7M
Q1 25
$8.4M
$-167.8M
Q4 24
$13.2M
$-79.5M
Q3 24
$27.5M
$-68.6M
Q2 24
$17.6M
$-79.0M
Q1 24
$13.7M
$-193.9M
FCF Margin
OSW
OSW
RARE
RARE
Q4 25
6.2%
-48.6%
Q3 25
10.7%
-58.0%
Q2 25
7.3%
-66.5%
Q1 25
3.8%
-120.5%
Q4 24
6.1%
-48.3%
Q3 24
11.4%
-49.2%
Q2 24
7.8%
-53.7%
Q1 24
6.5%
-178.2%
Capex Intensity
OSW
OSW
RARE
RARE
Q4 25
2.1%
0.5%
Q3 25
2.2%
0.8%
Q2 25
1.1%
1.5%
Q1 25
0.8%
1.0%
Q4 24
1.5%
0.1%
Q3 24
0.5%
1.2%
Q2 24
0.5%
1.4%
Q1 24
0.6%
3.0%
Cash Conversion
OSW
OSW
RARE
RARE
Q4 25
1.65×
Q3 25
1.36×
Q2 25
1.02×
Q1 25
0.66×
Q4 24
1.15×
Q3 24
1.33×
Q2 24
1.19×
Q1 24
0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OSW
OSW

Services$197.3M82%
Products$44.8M18%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons